International Journal of Clinical Oncology

, Volume 22, Issue 1, pp 59–69 | Cite as

Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer

  • Yasuyuki Ikezawa
  • Jun Sakakibara-Konishi
  • Hidenori Mizugaki
  • Satoshi Oizumi
  • Masaharu Nishimura
Original Article



The Notch receptor plays an important role in various cell fate decisions during development and in cancer. We have previously reported that Notch3 is upregulated by radiation in non-small cell lung cancer (NSCLC) cell lines and that the Notch pathway inhibitor γ secretase inhibitor GSI (gamma-secretase inhibitor), when combined with radiation therapy, significantly suppressed the growth of lung cancer cells. However, little is known about the mechanism of Notch upregulation induced by radiation. Based on reports of Notch expression being activated through the hypoxia inducible factor 1 (HIF-1) under hypoxic conditions, we hypothesized that HIF-1 would be involved in radiation-induced Notch activation in NSCLC.


Changes in HIF-1 and Notch expression in two Notch expressing NSCLC cells line after radiation treatment were examined using Western blotting. Notch expression was evaluated after the suppression of HIF-1α by small interfering RNA. The cytotoxic effect of YC-1, a HIF inhibitor, GSI and radiation was examined using the MTT assay in vitro and the xenograft model.


We found radiation-induced expression of HIF-1α protein at 2–6 h after treatment and upregulated expression of Notch3 protein at 24 h after treatment under hypoxic conditions. Specific suppression of HIF-1α expression downregulated the radiation-induced Notch3 activation, suggesting that the Notch pathway is activated though HIF-1α after radiation. An antitumor effect of YC-1 was evident under hypoxic conditions only when there was simultaneous radiation treatment. GSI and YC-1 had a synergistic antitumor effect in vitro, and the combination of GSI and YC-1 showed the greatest radiosensitivity in vivo.


Radiation-induced upregulation of the Notch pathway and HIF-1α protein may be potential therapeutic targets for more effective radiation therapy.


Notch HIF-1 Hypoxia Radiosensitivity Lung cancer 

Supplementary material

10147_2016_1031_MOESM1_ESM.pptx (990 kb)
Supplementary material 1 (PPTX 990 kb)
10147_2016_1031_MOESM2_ESM.pptx (626 kb)
Supplementary material 2 (PPTX 626 kb)
10147_2016_1031_MOESM3_ESM.pptx (417 kb)
Supplementary material 3 (PPTX 417 kb)


  1. 1.
    Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics. CA Cancer J Clin 65(2):87–108. doi: 10.3322/caac.21262
  2. 2.
    Allenspach EJ, Maillard I, Aster JC et al (2002) Notch signaling in cancer. Cancer Biol Ther 1(5):466–476CrossRefPubMedGoogle Scholar
  3. 3.
    Iso T, Kedes L, Hamamori Y (2003) Hes and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194(3):237–255CrossRefPubMedGoogle Scholar
  4. 4.
    Weignmaster G, Kopan R (2006) A garden of Notch-ly delights. Development 133(17):3277–3282CrossRefGoogle Scholar
  5. 5.
    Das I, Craig C, Funahashi Y et al (2005) Notch oncoproteins depend on gamma-secretase/presenilin activity processing and function. J Biol Chem 279(29):30771–30780CrossRefGoogle Scholar
  6. 6.
    Curry CL, Reed LL, Golde TE et al (2005) Gammma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene 24(42):6333–6344PubMedGoogle Scholar
  7. 7.
    Duechler M, Shehata M, Schwarzmeier JD et al (2005) Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with down regulation of CD23 and inactivation of Notch2. Leukemia 19(2):260–267CrossRefPubMedGoogle Scholar
  8. 8.
    Reedijk M, Odorcic S, Chang L et al (2005) High-level co-expression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65(18):8530–8537CrossRefPubMedGoogle Scholar
  9. 9.
    Haruki N, Kawaguchi KS, Eichenberger S et al (2005) Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 65(9):3555–3561CrossRefPubMedGoogle Scholar
  10. 10.
    Konishi J, Kawaguchi KS, Vo H et al (2007) Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67(17):8051–8057CrossRefPubMedGoogle Scholar
  11. 11.
    Mizugaki H, Sakakibara-Konishi J, Ikezawa Y et al (2012) γ-Secretase inhibitor enhances sntitumor effect of radiation in Notch-expressing lung cnacer. Br J Cancer 106(12):1953–1959CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Harris AL (2002) Hypoxia—a key regulatory factor in tumor growth. Nature Reviews Cancer 2(1):38–47CrossRefPubMedGoogle Scholar
  13. 13.
    Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8(2):99–110CrossRefPubMedGoogle Scholar
  14. 14.
    Moeller BJ, Dewhirst MW (2006) HIF-1 and tumor radiosensitivity. Br J Cancer 95(1):1–5CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dewhirst MW, Cao Y, Moeller BJ (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev 8(6):425–437CrossRefGoogle Scholar
  16. 16.
    Gustafsson MV, Zheng X, Pereira T et al (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Development 9(5):617–628Google Scholar
  17. 17.
    Dang TP, Gazdar AF, Virmani AK et al (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92(16):1355–1357CrossRefPubMedGoogle Scholar
  18. 18.
    Konishi J, Yi F, Chen X et al (2010) Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 29(4):589–596CrossRefPubMedGoogle Scholar
  19. 19.
    Chao C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446CrossRefGoogle Scholar
  20. 20.
    Chao C, Mu Y, Hallahan DE et al (2004) XIAP and surviving as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23(42):7047–7052CrossRefGoogle Scholar
  21. 21.
    Yeo EJ, Chun YS, Cho YS et al (2003) YC-1: a potential anticancer drug targeting Hypoxia-Inducible factor 1. J Natl Cancer Inst 95(7):516–525CrossRefPubMedGoogle Scholar
  22. 22.
    Yasui H, Ogura A, Asanuma T et al (2008) Inhibition of HIF-1α by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer 99(9):1442–1452CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Moon SY, Chang HW, Roh JL et al (2009) Using YC-1 to overcome the radioresistance of hypoxia cancer cells. Oral Oncol 45(10):915–919CrossRefPubMedGoogle Scholar
  24. 24.
    Harada H, Itasaka S, Zhu Y et al (2009) Treatment regimen determines whether an HIF-1α inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 100(5):747–757CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26(2):241–248CrossRefPubMedGoogle Scholar
  26. 26.
    Zhu Y, Zhao T, Itasaka S et al (2013) Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radiaresistance of perinecrotic tumor cells. Oncogene 32(16):2058–2068CrossRefPubMedGoogle Scholar
  27. 27.
    Chen Y, DeMarco MA, Graziani I et al (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67(17):7954–7959CrossRefPubMedGoogle Scholar
  28. 28.
    Lu X, Kang Y (2010) Hypoxia and hypoxia inducible factors: master regulators of metastasis. Clin Cancer Res 16(24):5298–5935CrossRefGoogle Scholar
  29. 29.
    Chen J, Imamura N, Chen H et al (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increase cell migration and invasion. Br J Cancer 102(2):351–360CrossRefPubMedGoogle Scholar
  30. 30.
    Sahlgre C, Gustafsson MV, Jin S et al (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105(17):6392–6397CrossRefGoogle Scholar
  31. 31.
    Qiang L, Wu T, Zhang HW et al (2011) HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma cells by activating Notch signaling pathway. Cell Death Differ 19(2):284–294CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Semenza GL, Roth PH, Fang HM et al (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia inducible factor 1. J Biol Chem 269(38):23757–23763PubMedGoogle Scholar
  33. 33.
    Carmeliet P, Dor Y, Herbert JM et al (1998) Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692):485–490CrossRefPubMedGoogle Scholar
  34. 34.
    Patiar S, Harris AL (2006) Role of hypoxia-inducible factor-1 as a cancer therapy target. Endocr Relat Cancer 13[Suppl 1]:s61–s75CrossRefPubMedGoogle Scholar
  35. 35.
    Yan M, Plowman GD (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 13(24):7243–7246CrossRefPubMedGoogle Scholar
  36. 36.
    Thurston G, Noguera-Troise I, Yancopoulos GD (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev 7(5):327–331CrossRefGoogle Scholar
  37. 37.
    Thurston G, Kitajewski J (2008) VEGF and Delta-Notch: interacting signaling pathways in tumour angiogenesis. Br J Cancer 99(8):1204–1209CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2016

Authors and Affiliations

  • Yasuyuki Ikezawa
    • 1
  • Jun Sakakibara-Konishi
    • 1
  • Hidenori Mizugaki
    • 1
  • Satoshi Oizumi
    • 1
  • Masaharu Nishimura
    • 1
  1. 1.First Department of MedicineHokkaido University School of MedicineKita-ku, SapporoJapan

Personalised recommendations